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Ethical issues that arise during the care of a pregnant woman with cancer are challenging
to physicians, policymakers, lawyers, and the bioethics community. The main purpose of
this scoping review is to summarize existing literature regarding the bioethical dilemmas
when a conflict arises in the maternal-fetus dyad, like the one related to cancer and
pregnancy outcomes. Moreover, we illustrate the decision-making process of real-life
case reports. Published data were searched through the PubMed and Google Scholar
databases, as well as in grey literature, using appropriate controlled keywords in English
and Portuguese. After identification, screening, eligibility and data extraction from the
articles, a total of 50 was selected. There are several established ethical frameworks for
conflict resolution and decision-making. Pragmatic theoretical approaches include case-
based analysis, the ethics of care, feminist theory, and traditional ethical principlism that
scrutinizes the framework of autonomy, justice, beneficence, and non-maleficence. In
addition, society and practitioner values could mediate this complex ethical interplay. The
physician must balance autonomy and beneficence-based obligations to the pregnant
woman with cancer, along with beneficence-based obligations to the fetus. Ethical
challenges have received less attention in the literature, particularly before the third
trimester of pregnancy. Best, unbiased and balanced information must be granted both
to the patient and to the family, regarding the benefits and harms for the woman herself as
well as for the fetal outcome. Based on a previously validated method for analyzing and
working up clinical ethical problems, we suggest an adaptation of an algorithm for
biomedical decision-making in cancer during pregnancy, including recommendations
that can facilitate counseling and help reduce the suffering of the patient and her family.
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Cancer is the second and first most common cause of death in
women aged 25–34 and 35–65 years, respectively (1). However,
cancer that occurs during pregnancy is a relatively rare event,
with an estimate between 0.03 and 0.1% of all pregnancies. The
incidence is expected to upsurge with later childbearing age and
unplanned pregnancies. In Europe, 3,000–5,000 patients are
diagnosed yearly with cancer during pregnancy, whereas 3,500
cases are reported in the USA (2–5). The most common
neoplasms that occur during pregnancy are breast cancer,
thyroid, cervical, ovarian and melanoma (2–5), but the
currently available data is mainly limited to those areas of
Western/Central Europe and North America (6, 7). Some
recent data indicate that other cancers may be more prevalent
in pregnant women in particular regions, as more cases of
melanoma in Scandinavia (8) and gastrointestinal cancer in
Asia (9).
The problematics of how to handle cancer during pregnancy
has been a long-term matter of debate in the medical
community. The many ethical issues that arise in the care of
pregnant women involve many stakeholders—such as family,
physicians, legislators, jurisdiction and the bioethics community
- and its boundaries are imperfect since many contexts intersect.
In the care of pregnant cancer women, it is important to consider
the status of two biologically-related patients, but individually
viable. However, cancer during pregnancy represents a dilemma
given that treatment should be directed to keep two lives: maternal
and fetal. Despite this complex ethical interplay, it should
be emphasized, with the exception of special circumstances,
that the patient has the final word in the decision-making
process and that the remaining stakeholders contribute with a
variable role and weight depending on each specific case
and scenario.
This article focuses on the discussion to the clinical/
pharmacological background and ethical issues that emerge
from the medical management, especially before the third
trimester, of a pregnant woman with cancer, which occurs
whenever the therapy toxicity creates a conflict of interest that
unbalances cancer and pregnancy outcomes. Furthermore, in
order to permit a better framing of this problematic, we describe
real-life paradigmatic cases that allow us to highlight the
idiosyncrasies related to the ethical approach to cancer during
pregnancy. Finally, we suggest an adaptation of an algorithm for
biomedical decision-making in cancer during pregnancy,
including some recommendations that can facilitate counseling
and help reduce the suffering of the patient and her family.Abbreviations: AFP, Alpha-fetoprotein; AMH, Anti-Müllerian hormone; ATRA,
All-trans-retinoic acid; Bcr-Abl, Breakpoint cluster region protein-Abelson
murine leukaemia viral oncogene homolog 1; CA, Carbohydrate antigen; G-
CSF, Granulocyte colony-stimulating factor; GM-CSF, Granulocyte colony-
stimulation factor; HE-4, Human epididymis protein-4; I-131, Radioactive
iodine; LDH, Lactate dehydrogenase; mGy, mili Gray units; PD-1, Programmed
cell death protein-1; PD-L1, Programmed cell death protein-ligand 1; SCC,
Squamous cell carcinoma; US, Ultrasonography; USA, United States of America.
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Assessing reasons or arguments presented in the normative
bioethics’ literature can be a tricky task, as identifying any
relevant data on a given topic in bioethics can be time-
consuming and not always possible due to the high burden of
grey literature, including books, edited book volumes and even
predatory magazines, some of them with dubious content.
Therefore, some authors argue that, even if the systematic
search should be maintained in bioethics research, the type of
methodology will depend on the research question. In some
cases, identifying all the literature on a given question may not be
feasible and, even if it is, the time spent will not add significant
value to the research (10, 11).
That is why some advocate a turn to critical interpretative
reviews which might better serve bioethics research purposes
(11). Based on that, we chose the scoping review as the best
methodology for our research objectives, which were to rapidly
map the existing literature (including the one not indexed in
major databases, such as the grey literature), chart data from the
studies, and clarify concepts. We were not interested in asking a
single or precise question, but more focused on the identification
of certain concepts in papers or studies, and in the mapping,
reporting or discussion of the data collected. Our aim with this
review is to summarize and clarify the existing published
literature on the ethical dilemmas interwoven into the
dimension of pregnant women with cancer, particularly before
the third trimester. Moreover, we put in perspective the potential
ethical problems and frameworks regarding the more
appropriate approach for specific and representative case reports.
We developed an a priori protocol to define our research
objective, and methods, which informed our selection for
data extraction.
On October 8-9th, published literature was searched between
2010 and 2020 through the PubMed, using appropriate
controlled keywords: [“ethics” (MeSH) OR “ethical” (MeSH)]
AND [“carcinoma” (MeSH) OR “cancer” (MeSH) OR
“neoplasm” (MeSH)] AND [“pregnancy” (MeSH) OR
“pregnant” (MeSH) OR “gestation” (MeSH)]. References from
the selected articles were scanned in order to identify
other papers.
By the author’s decision, other relevant articles beyond this
scope, including grey literature, have been included. For that
purpose, we used Google Scholar search engine with the
controlled words in English and Portuguese (“ethics” AND
“cancer” AND “pregnancy”) OR (“ética” AND “cancro” AND
“gravidez”), respectively.
Using Covidence (Covidence.org), we inputted our inclusion/
exclusion criteria and selected the articles independently by two
reviewers (DAC, JGN).
The inclusion criteria defined included: 1) patients who are
pregnant; 2) patients who have active cancer; 3) articles addressing
the problem of the triad: ethics, cancer and pregnancy; 4) articles
including an ethical perspective during pregnancy; 5) articles and
expert meeting reporting clinical practice guidelines or
recommendations for cancer management during pregnancy; 6)
study based on the toxicity of antineoplastic treatment duringDecember 2020 | Volume 10 | Article 598508
Alpium Costa et al. Cancer, Pregnancy, and Bioethical Dilemmaspregnancy that includes one of the following: chemo-, hormone-,
targeted-, immuno-, and radio-therapy; 7) study based on the
toxicity of supportive medication during pregnancy; 8) article
language in English or Portuguese; 9) articles must be available
with full-text.
The exclusion criteria were: 1) premenopausal women and
fertility issues; 2) cancer risk exclusively after pregnancy; 3) cancer
risk and hormone replacement therapy; 4) active cancer and
breastfeeding; 5) articles discussing cancer therapeutics exclusively;
6) articles not mentioning pregnancy, cancer, and ethics at all.
Data extraction was conducted in Microsoft Excel version 16.41
(20091302) using a data charting form developed for our protocol.RESULTS
Results were mostly restricted to review articles, ethical
perspectives, clinical practice guidelines and case-based
teaching guides (only available English and Portuguese text).
Afterwards, the screening and selection of articles, quality
assessment, and data extraction were performed independently
by two reviewers (DAC, JGN), according to the pre-planned
inclusion and exclusion criteria. Conflicts were resolved by a
third party (IG) when a consensus was not reached.Frontiers in Oncology | www.frontiersin.org 3For the period between 2010 and 2020, the initial search in
English yielded 633 publications after the possible combinations
of keywords in PubMed. Excluding the 292 duplicates, the
number was reduced to 341. Title screen reduced the selection
to 75 papers for reviewing abstracts and 61 fulfilled the criteria
for reading the full-text. In the final selection, 12 articles were
chosen to be included in this review (Figure 1).
The initial search in Google Scholar with the English
keywords (“ethics” AND “cancer” AND “pregnancy”) resulted
in 330.000 publications. By limiting the search between 2010 and
2020, 81.200 articles were retrieved. Furthermore, when
searching for the Portuguese keywords (“ética” AND “cancro”
AND “gravidez”), 3,150 papers were found. By limiting the
search between 2010 and 2020, 2.680 publications were retrieved.
Twenty-nine additional articles in English and Portuguese,
also indexed in PubMed, were included in this review and served
as a reference to some of the previously searched articles. This
second subgroup of articles included pioneering and relevant
articles published in reference journals, as well as clinical trials
and international guidelines/consensus.
Finally, a third subgroup of 10 publications was considered,
which, despite not being indexed in databases, added value to the
literature review. This group of articles was heterogeneous, with
texts corresponding to international guidelines or to a healthFIGURE 1 | Flowchart explaining the article selection strategy (adapted from PRISMA, 2009).December 2020 | Volume 10 | Article 598508
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and Portuguese), and case-based teaching guides.DISCUSSION
About Cancer During Pregnancy
The knowledge about the effect of cancer during pregnancy and
the effect of cancer progression in pregnancy is of crucial
importance for the success of the mother’s treatment and
favorable outcome for the fetus. There are contradictory
reports that have been published regarding the outcomes of
these patients.
In 1880, Samuel Gross stated that breast cancer during
pregnancy would behave like a rapidly growing disease,
including with an “excessively malignant” clinical course (12).
In 1943, after treating 20 patients with breast cancer, a group at
Columbia University Presbyterian Hospital concluded that
pregnancy “made the disease inoperable” (13). Ten years later,
it was consensual that abortion was linked to improved patient
survival (12). A population-based cohort study of 15,721 women
diagnosed with breast cancer, of whom 1,110 (7%) had cancer
during or within 2 years after pregnancy, revealed that this subset
of patients had a worse prognosis, validating previous data (14).
Conversely, a multicentric registry containing 447 women with
breast cancer during pregnancy and 865 non-pregnant
counterparts, showed similar overall-survival in both groups,
after adjusting for known prognostic factors (15). Nonetheless, a
careful interpretation of these studies should be taken, given the
heterogeneity of the patient populations and treatments
prescribed (16).
So far, there is no consolidated expert opinion on whether
pregnancy can induce the occurrence or relapse of cancer and if
it correlates only with maternal or also with other external or
endogenous risk factors.
Complementary Diagnostic Exams and
Trimester Considerations
During the last decades, imaging of the pregnant patient has been
performed with radiography, computed tomography, magnetic
resonance imaging, scintigraphy, positron emission tomography
scan, and ultrasonography (US). US imaging has emerged as the
primary imaging modality because it provides real-time images
without the use of ionising radiation (16).
A clear link between the severity of fetus impairment,
gestational stage, and cumulative radiation dose received has
already been established (16). For instance, during the
organogenesis, there is a higher likelihood of major induction
malformations and the threshold dose is above 100 mGy. There
are also other issues besides ionising radiation. The radioactive
iodine (I-131) crosses the placenta and has the ability to affect
fetal thyroid and gadolinium teratogenic in animal studies. More
invasive imaging tests should only be performed if the diagnosis
and/or staging is expected to contribute decisively to the
prognosis of the mother or fetus and that the risks and benefits
are perfectly clarified and understood by the mother (16, 17).Frontiers in Oncology | www.frontiersin.org 4Although the fetus is unscathed by laboratory tests, our main
concern will be the influence that pregnancy will have on
diagnosis, staging and follow-up, due to the fact that the serum
biomarkers lack sensitivity and specificity during this period.
There are tumor biomarkers that may be increased, such as CA
15-3, SCC, CA 125, and AFP, and others that are not so much,
such as the example of CEA, CA 19-9, LDH, AMH, and HE-4.
Inhibin B and LDH increased in the last trimester may be a
laboratory sign of hypertensive abnormalities linked to
pregnancy (4).
Treatment Options and Trimester
Considerations
The main challenge while managing cancer in pregnancy is
balancing therapeutic regimen and fetus welfare. In addition,
as an estimated 50% of pregnancies are unplanned, many women
are exposed to teratogens before realising they are pregnant (13).
This condition demands attention and careful protocols.
Approximately 0.5% of all births occur before the third
trimester of pregnancy and the majority of these very early
deliveries result in neonatal deaths and more than 40% in
infant deaths. The delivery before 23 weeks of gestation,
usually leads to neonatal death (5%–6% survival), and among
rare survivors remains significant morbidity (98%–100%). When
delivery is anticipated near the limit of viability, the patient,
families and healthcare teams are faced with complex and
ethically challenging decisions (18, 19). For most cytotoxic and
targeted therapies, there is a lack of data regarding the risk of
teratogenesis, based on case reports and retrospective series. The
potential mutagenic, teratogenic and carcinogenic effects of
ionising radiation and cytotoxic agents in the embryo are well
known and depend on the dose, nature of the compound,
treatment field and gestational stage. Some authors advocate
that, if pregnancy occurs while the patient is under endocrine
treatment (e.g., tamoxifen) or chemotherapy, a pregnancy
termination should be recommended if it is done in the
first trimester.
Surgery
In general, surgery can be performed during any stage of
pregnancy with robust evidence demonstrating the safety of
surgical procedures and most anaesthetic agents seem to be
safe for the fetus. However, the risk of miscarriage is slightly
incremented (1%–2%), especially in the first trimester. In
addition, there is a higher risk of low birth weight and
premature delivery (1.5–2 times relative risk), an increased rate
of complications and higher morbidity in major abdominal and
pelvic procedures. Relatively to anaesthetic drugs, there is a
record of good safety and none of them stands in the drug list
of proven teratogens. Given the fact that there is a minimal risk
to the fetus and potential benefits of the treatment, there should
not be any delay on the surgery, if indicated (2–4, 16).
Radiotherapy
The embryo-fetal risk can also be influenced by radiotherapy co-
treatment and doses higher than 50–100 mGy should be avoided.
Below these doses, there is a low risk of stochastic biologicalDecember 2020 | Volume 10 | Article 598508
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developmental disorders) are as frequent as in general
population (3%–5%) (2, 4, 20). In certain cases, it is necessary
to use radiotherapy in the tumor, so the clinician must use it, in
the period that it is least harmful to the fetus. From 2 to 12 weeks,
the use of radiation has the risk of teratogenesis and growth
retardation. Until 20 weeks, the fetus can present mental and
growth retardation, microcephaly, eye, palate and genital
deformities and beyond that, there is an increased risk of
sterility, malignancies, and genetic defects (2–4, 16).
Chemotherapy
The most sensitive and critical period of drug exposure is
organogenesis, which occurs roughly 2–8 weeks post-
conception (17), especially during the gastrulation period when
tissues are differentiating rapidly, and damage becomes vast and
irreparable (21). Therefore, during the first trimester, the risk of
spontaneous abortions, fetal death and major congenital
malformations are increased, reaching 10%–20% and decline to
about 6% when folate antagonists like methotrexate are excluded.
The effects of antineoplastic agents during the second trimester
are related to intrauterine growth restriction, low birth weight,
miscarriage, and premature birth (20%–40%) (2–4). During the
perinatal period, the effects are related to maternal/fetal
myelosuppression, infections, and haemorrhage. Long-term
outcomes of children exposed to chemotherapeutic agents in
utero are not well examined. It is known that it is safe to give
some drugs during the third trimester without causing long-term
damage to the baby, for example, for Hodgkin´s disease or breast
cancer (22).
Endocrine Treatment
In contrast to non-pregnant counterparts, pregnancy-associated
breast cancer is more likely to develop higher stage tumors,
more poorly differentiated, and less common oestrogen
or progesterone-receptor positivity. These results were
corroborated by previous studies. Nevertheless, there is still a
significant fraction of hormone-receptors positive breast
cancer (23).
However, many of the physiological changes during
pregnancy are hormone-driven. Furthermore, the blockade of
oestrogen (e.g., with tamoxifen), which is frequently used in
hormone-positive breast cancer, might interfere with these
physiological modifications and can be teratogenic and
associated with fetal death and birth defects, mainly
craniofacial anomalies (preauricular skin tags, microtia,
hemifacial microsomia), ambiguous genitalia (clitoromegaly,
labial fusion), and acetabular and sacral dysplasia. Tamoxifen
is also associated with vaginal bleeding and miscarriage.
Moreover, tamoxifen is not recommended during the lactation
period, as it delays milk production, and there are limited safety
data regarding its excretion in human milk. Importantly, the
decision to postpone the tamoxifen to allow lactation should be
based on individual risk and include a balanced discussion
between risk and benefit (3, 4, 16, 20, 24). However, the
tamoxifen effects on the fetus and the course of pregnancy are
not yet fully understood (24).Frontiers in Oncology | www.frontiersin.org 5Targeted Agents
Most of these targeted agents commonly used in breast cancer,
such as trastuzumab, pertuzumab, bevacizumab, among
others, should not be used because they present some
undesirable adverse effects, but also due to the fact that there is
missing much information yet. In general, human epidermal
growth factor receptor 2 agents are safe during the first
trimester, although during the second and third trimesters
oligohydramnios, pre-term delivery and neonatal deaths may
be present. Rituximab, an anti-CD20, imatinib, an anti-Bcr-Abl
tyrosine kinase, and ATRA, a trans-retinoic acid, can be used
with caution, even though they cross the placenta. Rituximab is
safe in the first trimester, but in the coming trimesters, it causes
cytopenia and B cell depletion, reversible at birth, while imatinib
is safe in the second and third trimesters, with the risk of causing
major malformations in the first trimester. ATRA is mainly
dangerous in the first trimester due to the risk of abortion. The
only targeted agent safe throughout pregnancy is interferon-a (3,
4, 16, 20, 25, 26).
Immunotherapy
A plethora of immunotherapy options is being used in the
investigation and active treatment of several malignancies. As
it is a more recent treatment, there is not much information
regarding the security of these drugs during human pregnancy.
However, as we all know, mother and fetus are not genetically
identical. Therefore, an immunological tolerance from the
mother towards the fetus is necessary in order for the
pregnancy to develop successfully (26).
Immune checkpoints, such as programmed cell death
protein-1 (PD-1), PD-1 ligand (PD-L1), and cytotoxic T-
lymphocyte–associated protein 4, play a crucial role in the
process aforenamed. Consequently, the fetus can be harmed by
an aggressive immune response after the inhibition of these
immune checkpoints. Furthermore, the drugs that can inhibit
the checkpoints are immunoglobulins G4 antibodies that have
the ability to cross the placenta and cause toxicity directly to the
fetus. In animal models, these drugs demonstrated that their use
could increase abortion rates, stillbirths, premature delivery and
higher incidence of infant mortality, namely in the third
trimester. However, there was not an increase in fetus
malformations. In summary, since these drugs are so recent
and have so little information regarding their security among
pregnant women, immune checkpoint inhibitors are not
recommended (26).
Supportive Medication
Our concern about pregnancy in women with cancer should not
only focus on antineoplastic agents, but even on non-
antineoplastic agents used in clinical cancer practice, such as
bisphosphonates, granulocyte colony-stimulating factor (G-CSF)
or granulocyte-macrophage colony-stimulating factor (GM-
CSF), antiemetics, analgesics, and anti-inflammatories (2–4, 16,
20, 26).
Because bisphosphonates inhibit bone resorption, they are
used in the treatment of hypercalcemia, osteoporosis, metastatic
bone disease, and Paget disease. The bisphosphonates inhibitDecember 2020 | Volume 10 | Article 598508
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that of other antiresorptive agents. In addition to their inhibitory
effect on osteoclasts, bisphosphonates appear to have a beneficial
effect on osteoblasts. These biological effects can lead to a
reduction in serum calcium in the maternal blood and its
availability to the fetus, which might induce skeletal
malformations, reduced bone growth and low birth weight. It
can, inclusively, affect parturition adversely by reducing uterine
contractions. Therefore, it is contraindicated during pregnancy
(3, 20).
G-CSFs/GM-CSFs are recommended in cases of severe
neutropoenia or as primary/secondary prophylaxis during
treatment with some chemotherapy regimens. Its safety during
the pregnancy period is still unknown. In animal studies, it seems
to cross the placenta and increase the rate of spontaneous
abortion and low birth weight (2, 3). However, G-CSFs have
already been used during pregnancy, without complications.
Thus, these agents may also be considered during pregnancy if
a high risk of neutropoenia is forwared (2, 3, 16, 26).
Antiemetics (metoclopramide, cyclizine, meclozine, alizapride,
ondansetron, and aprepitant) can be safely used during the first
trimester of pregnancy. The safety of corticosteroids is variable, with
the use of hydrocortisone and prednisolone being preferred to
dexamethasone or betamethasone, as they are extensively
metabolized in the placenta and relatively little detected in the
fetal compartment. Repeated administrations of betamethasone are
associated with attention problems and cerebral palsy. Analgesics
(paracetamol, opioids, anti-inflammatory agents), with the
exception of the first trimester, did not generate side effects, but
there is some risk of respiratory depression and fetal ductus
arteriosus closure (3, 4, 16).
The Ethical Issue: Balancing Interests
Pregnancy appears as an exceptional circumstance in medical
ethics as the primary medical principle Primum non nocere can
be questioned, as the access to the fetus occurs exclusively
through intervention on the pregnant mother and treating the
mother may imply harming the fetus. This is a unique situation
since the welfare of both mother and fetus must be considered on
any treatment planning.
When a conflict arises in the maternal-fetus dyad, caregivers
must understand the pregnant woman´s mindset, broad social
network, values, cultural, and religious beliefs, as this may impact
their decisions (27). Consequently, it is imperative to promote
the autonomy and physical integrity of the pregnant woman,
ensuring that all available information on pregnancy and cancer
outcomes is provided in order to allow for a fully informed
consent consistent with her values (28) since the woman’s
decision is absolute and unlimited. Therefore, in cases when
the woman’s decision may harm her fetus (e.g., treatment of
cancer during the first trimester) coercion to force treatment is
never justified.
To date, there is no data systematically collected reporting the
decision-making process of women who had cancer and
pregnancy at the same time. Although, there are two studies
conducted in the United Kingdom reporting patient experiencesFrontiers in Oncology | www.frontiersin.org 6with participation in ORACLE (29) (evaluate the possibility that
treatment with antibiotics prolongs labor and improves neonatal
outcomes in women who are less than 37 weeks pregnant and
experiencing either pre-term labor or premature rupture of
membranes) and in the Magpie Trial (30) (prophylactic use of
anticonvulsants for women with severe preeclampsia). In these
studies, the major motivating factors were identified as self-
benefit (it can help treat mother condition), benefit for your child
(it can minimize the associated risks for the fetus) and altruism
(participation can help future women or is it for the sake of
medical science). It was also shown that, although some women
seek the opinion of family and friends, they have little
involvement or influence in women’s decisions. The partners
played a role in providing a second opinion for many women,
but study participants rejected the idea that their relatives or
friends were in a position to influence their decision. In parallel,
it may be reasonable to consider, in the future, the option of
offering pregnant women with cancer the possibility of
participating in clinical trials and/or enrolling in registries,
increasing the motivation and the expectation of benefits for
them and the fetus.
In the child-to-be perspective, there are extra layers of ethical
complexity to address, because the antineoplastic treatment
typically affects not only the pregnant woman but also the
fetus. The developing fetus clearly has no capacity for
autonomous choice, and there is no formula for balancing the
interests and moral claims of the fetus with those of the mother.
Furthermore, the welfare of the fetus is typically not independent
of the interests of its mother (31).
When a conflict arises in the maternal-fetus dyad, such as
cancer treatment and the risk of fetal demise, a range of ethical
frameworks may be useful in the decision-making process. It is
clear that the physician has beneficence-based and autonomy-
based obligation to the pregnant cancer patient (32). Because of
an immature central nervous system, the fetus cannot
meaningfully be said to possess values and beliefs, although
this is tremendously arguable.
Hence, scientifically there cannot be autonomy-based
obligations to any fetus, although women’s beliefs may hasten
her to judge differently (32). However, the physician can have
beneficence-based obligations to the fetus, if the fetus is
considered as a patient (33). The pregnant woman is free to
withhold patient status, confer patient status, or, after conferring
it, withdraw it from her pre-viable fetus (32). The fetus has no
claim to patient status independently of the pregnant woman’s
autonomy. When the woman is uncertain about or is not able to
confer the status, the fetus can be provisionally regarded as a
patient (32, 33). However, these approaches have been criticized
for their tendency to emphasize the divergent rather than shared
interests of the pregnant woman and the fetus. In fact, in most
cases, the interests of the pregnant woman and fetus actually
converge (28).
Whenever a pregnant woman is presented with a cancer
diagnosis, several ethical concerns addressing technicalities
must be approached, while keeping in mind the surrounding
emotional issues.December 2020 | Volume 10 | Article 598508
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which raises pertinent questions: i) should the patient be
included in the decision-making to the best of her abilities in a
limited way, or should paternalistic decision-making take over?
ii) Should a proxy decision-maker decide based on the perceived
patient’s best interest? (20) These are queries that can be carefully
grasped by solving real-life cases, in parallel those that will be
presented later.
To allow for an informed decision, the patient must be well
aware of multiple medical facts, such as cancer prognosis, the
possibilities of antineoplastic therapy, its main toxicities and its
aim, namely: whether curative or palliative, if it will improve quality
of life, or overall and progression-free-survival, if there is a risk of
pre-term delivery or if peripartum complications are expected.
The timing of treatment must also be considered—is the
mother symptomatic and needs to initiate treatment quickly or is
it possible to delay it until the third trimester, when there is no
significant risk for fetal defects in a short and long-term? Besides
technical issues, before starting the treatment, the physician must
consider emotional issues, such as the possibility of the child-to-
be meeting its mother.
There are several established ethical frameworks for conflict
resolution and decision-making. Pragmatic theoretical
approaches include case-based analysis, the ethics of care,
feminist theory, and traditional ethical principlism that
scrutinizes the framework of autonomy, justice, beneficence,
and non-maleficence. In addition, society and practitioner
values could benefit this complex process.
Illustrative Cases of Bioethical Dilemmas
and a Proposed Algorithm for Ethical
Decision-Making
For instance, the 1987 paradigmatic case of a pregnant woman in
her late 20s, who had a late lung relapse 15 years after Ewing´s
sarcoma diagnosis brought these issues to ahead. Although fully
committed to saving her life, at the end of the second trimester, it
became clear that the patient was dying. The Medical Centre
tried to insist upon an early Cesarean section delivery in order to
save her fetus. She refused the intervention with the support of
her family, knowing it would almost certainly kill her, but the
hospital forced the delivery through a court order. Both the
patient and her extremely premature baby survived for only a
short while after the surgery. In 1990, the Court of Appeals
posthumously vacated the court-ordered Cesarean section,
holding that the patient is totally autonomous to make
healthcare decisions for herself and her fetus and that only in
the most exceptional circumstances should a pregnant woman’s
right to refuse interventions be called into question (34). Despite
the media exposure of this case, others with similar ethical issues
were far from being elucidated (35–37).
This first case is an example of what should not be done in
ethical terms when approaching such a complex and sensitive
context. It was noticeable that there was no multidisciplinary
management and strategy for a balanced approach to outline
cancer and pregnancy facts of the case and the non-medical
issues to achieve the best ethical possible scenario (Figure 2).Frontiers in Oncology | www.frontiersin.org 7It is possible to infer that the woman would be in mental
conditions to take a position. Hence, all the best possible
information, at that moment, namely the cancer and
pregnancy outcomes for the woman, evidence-based treatment
options and available supportive measures for the situation,
should have been presented to the patient. Furthermore, the
comparison with previous similar ethical scenarios and the
consultation of guidelines should have been assessed and
discussed, in a multidisciplinary gathering, comprising the
whole medical specialities related to this subject (e.g., Medical
Oncology, Obstetrics, among others), a representative of the
ethics committee, all the stakeholders (such as the patient’s
family and the fetus’ father) and the patient itself. Finally, the
patient’s final decision, in collusion with the autonomy ethic’s
principle, should have been respected.
In 2016, on February 20, a 17-week-pregnant woman in her
late 30s, collapsed after an intracerebral haemorrhage, probably
related to a late recurrence of kidney cancer diagnosed 10 years
earlier (40). Soon after physicians declared her brain dead (41).
The hospital ethics committee and the family were enquired. It
was explained to both parties - mother’s family and the fetus’
father—that, to allow for the fetus survival, the woman should be
kept on life-sustaining treatment to reach at least its 32 weeks,
the earliest date doctors felt that a successful Cesarean delivery
would be possible (40). This emphasizes the role of the “mother’s
body as a cadaveric incubator”, “mother as the organ donor and
fetus as the recipient”, and the concern for “possible damages to
the fetus” (42–44). Some professionals believe that it is not
ethically acceptable to maintain the mother’s body after brain
dead to use it as a “fetal container.” Such a decision should not be
assumed, but it must be debated. If the mother is to be considered
a “cadaveric incubator” with no autonomous rights, the rights of
the fetus should legally prevail. Another argument claims that the
continued somatic support itself is actually organ donation with
the fetus as the recipient (42–44). The family strongly expressed
that the mother would have wanted her life preserved in order to
give the fetus a chance for survival. The ethics committee equated
the fetus life to a child at risk and allowed the support to the
brain-dead mother. The decision was taken in a meeting of the
neurosurgical, critical care, obstetrics, neonatal, transplant and
ethical staff, along with the patient’s family. One hundred seven
days later, the baby was born healthy, and the life-sustaining
machines were turned off (40, 41).
About 10 years earlier, a woman of the same age and
gestational stage as in the previous case suffered a stroke
secondary to the brain progression of melanoma. Soon after,
the doctors declared brain dead. Her family also decided to keep
her alive to give the fetus a chance. It became a race between the
fetus’ development and cancer that was ravaging the patient’s
body. The baby was born about 2 months prematurely, and
tragically did not survive. At that time, the case was also
considered to be notable because there was no controversy (43).
Put into perspective, the two aforementioned cases have
analogous ethical issues, however, with different endings.
Nevertheless, both these situations follow the best ethical possible
scenario approach (Figure 2). Since both patients were declaredDecember 2020 | Volume 10 | Article 598508
Alpium Costa et al. Cancer, Pregnancy, and Bioethical Dilemmasbrain dead, none of them would be mentally suitable to take a
position. Thus, the patient’s family and the fetus’ father should be
responsible for the decisions regarding equally the patient and the
fetus welfare. As observed, in these circumstances, all of the
stakeholders had received the best information possible vis-à-vis
the cancer and pregnancy outcomes, the evidence-based treatment
options to follow pregnancy and supportive measures for
maintenance of “cadaveric incubator”, with the aim for the
survival of the fetus. All the decisions were engaged with a
multidisciplinary team, taking into consideration previous
comparable clinical cases, and respecting the patient’s family and
fetus’ father autonomy. Since the number of cases describing the
management of extended maternal somatic support after brain
death is limited, every case should be continuously reassessed and
adapted along with the increasing experience and knowledge
(42–44).
In these difficult cases, mainly before the third trimester, the
sovereign decision should be taken after thorough discussion
between mother (or legal substitute) and the treating physician
(42–46). While respecting the principle of autonomy, another
final ethical issue is the right of the physicians to conscientiously
object to certain treatment options.
As stated before, physicians should not bias with their
recommendations and should present to consider three
scenarios: i) treatment during pregnancy, with close monitoring
for side effects and reconsideration of termination before viability;Frontiers in Oncology | www.frontiersin.org 8ii) treatment with termination of the pregnancy; and iii)
treatment delay until fetal lung maturity, when it’s reasonably
safe to deliver the baby (34, 47).
All over Europe, there are differences between countries
regarding availability, conditions and gestational limit. In
Portugal, since 2007, and after a National Referendum, the
voluntary termination of pregnancy until 10 weeks of gestation
was legalized (law n°16/2007). In that same legal document, it is
stated that in case of danger of death or physical and/or psychic
injury, the possibility of interrupting the pregnancy until 12
weeks of gestation is allowed (48).
The available international guidelines recommend that
maternal fetal medicine consultation should include counseling
on maintaining or terminating a pregnancy, including a review
of the treatment options. These guidelines support a framework
of shared decision-making in the context of maternal-fetal
conflict to provide guidance for compassionate conflict
resolution. An ethics consultation may be helpful to mediate
conflict resolution. Intervention by the courts is rarely
appropriate or indicated and should be avoided (27, 47, 49).
Based on a validated method for analysing and working up
clinical ethical problems, we suggest an adaptation of an
algorithm for biomedical decision-making in pregnancy-
associated cancer (Figure 2).
The first task in this ethical decision-making process is to
establish the medical and pregnancy facts of the case. The secondFIGURE 2 | Algorithm for biomedical ethical decision-making (adapted from Schenck (38) and Botha et al. (39)).December 2020 | Volume 10 | Article 598508
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challenging. These steps are followed by an assessment of the
goods relevant in the case. The immediate concern is clearly what
is suitable for the woman medically, but that is followed closely
by an attempt to understand the patient’s overall good—e.g.,
psychological good, good in terms of family and relations,
spiritual good, and good in terms of the patient’s preceding life
history and values. While ensuring the good of the woman is the
primary aim, this is insufficient in itself, as the goods of fetus and
others must also be considered (38).
The principles that apply in the case at hand are then evaluated,
specifying what a given principle means in this case and balancing it
against the moral claims of each of the others. In themselves,
principles can become mere abstractions, perhaps even sterile
nostrums for dealing with these complex ethical dilemmas.
Therefore, virtue ethics, another bioethical approach that has
received increased attention in recent years, addresses the nature
of the relationship between patient and healer, with particular
attention to the character of the physician (38). Pellegrino and
Thomasma have presented a detailed analysis of how they interpret
the virtues that are essential to medical practice. These virtues
include phronesis, compassion, fidelity, trust, integrity, self-
effacement, justice, fortitude, and temperance (50).
In any case, a consideration of the virtues and principles on
the one hand, and guidelines recommendations and prior similar
cases analysis on the other, provide more guidance for a right
answer to bioethical dilemmas.
Finally, the guidelines recommendations should be
accompanied by several steps that must take place in the “best
ethical possible scenario”, in order to enhance the quality of the
counseling and emotional support that are an essential part of
management (Figure 2):
• Assess the mental state of the patient;
• Ensure privacy;
• Suit medical language to the patient and the other
interlocutors;
• Be realistic and accurate about cancer and pregnancy outcomes;
• Ensure an unconditional availability for the discussion and re-
discussion of each dough or clarification.
• Encourage participation in the decision-making process of the
partner and the closest family members;
• Inform that medical management is not the responsibility of a
single professional, but of a multidisciplinary team with a
holistic approach;
• Provide evidence-based treatment options;
• Inform about other supportive measures;Frontiers in Oncology | www.frontiersin.org 9• Inform that the patient has the final word in the decision-
making process;
• Provide the necessary time for the information processing
phases according to Kübler-Ross model (denial, anger,
bargaining, depression, acceptance);
• Never take hope from the patient.CONCLUSIONS
Scientific and clinical data addressing the risks and the efficacy of
treating a pregnant woman with cancer have already been
explored in the literature. However, the imbricated ethical
challenges have received less attention, particularly before the
third trimester of pregnancy.
A pregnant woman with cancer faces the choice between best
antineoplastic treatment versus maximal fetal welfare. Best,
unbiased and balanced information about the benefits and
harms for the woman herself as well as for fetal outcome must
be granted both to the patient and to the family.
Halting, in this scoping review, the authors identified certain
concepts and discussed the heterogeneous data collected
regarding bioethical decisions on cancer during pregnancy.
Nevertheless, there are still some unsolved queries, that must
be discussed in multidisciplinary groups, and personalized to
each unique scenario. Each new decision should be included in
an updated shared and anonymous database to put in perspective
what should be done in a particular cancer situation that affects
two unique lives (maternal and fetal), allowing to gather attitudes
and experiences that fill a knowledge gap needed to develop
ethical care guidelines.AUTHOR CONTRIBUTIONS
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